NeuroElement Multi-Target Brain Optimization Formulation (22-brain-chemistry)
Inventory item: 8470 | SKU: 2051 | Line: Blueprints
Page: https://cri-one.com/22-brain-chemistry.html
Owner and author: Christopher Gabriel Brown (CRI-ONE)
Record date: 8 October 2026
1. The Record in Brief
NeuroElement Multi-Target Brain Optimization Formulation (22-brain-chemistry) is a research and engineering blueprint by Christopher Gabriel Brown (CRI-ONE): a computationally designed seven-compound formulation delivering 10 of 14 brain-essential chemical elements, the method that selected it, and the code, databases, drawings and U.S. application text behind it (Evidence 1, 8). It is a research and discovery IP record and makes no treatment claim. Its earliest dated disclosure is Invent Depositions, ISBN 978-1-979767-89-7, first shipped 24 November 2017, where deposition #769 on printed page 181 records the goal of achieving the proper chemicals in the brain without poisoning the other organs (Evidence 11, 12). Its USPTO anchor is U.S. Application No. 19/555,525, received 3 March 2026 at 05:06:50 PM ET, Confirmation No. [redacted], pending, joined by the pending umbrella U.S. Application No. 19/693,405 (Evidence 3, 5, 6). Its first cri-one.com store listing was created on 6 March 2026, and its current item page and card Buy button went live on 8 October 2026 (Evidence 13, 14, 15). Its text, drawings, code and data are marked "Copyright (c) 2026 Christopher Gabriel Brown. All rights reserved." (Evidence 2).
2. Proprietary - What Is Owned and How It Is Held
The source package at D:/special/22-brain-chemistry/ holds 90 working files (folder count of 8 October 2026, tool caches excluded) in six families:
- Code: 23 Python files, 5,998 lines: the 12-module brain_research package (database, compound analyzer, Supplement Facts generator, report generator, REST API), a command-line tool, three data scripts and a pytest suite whose cache records 52 test IDs and an empty last-failed list.
- Data: five JSON databases whose metadata records 65 neurotransmitters, 20 brain-critical elements, 54 brain diseases, 54 observation guides and 35 medicines, each naming Christopher Gabriel Brown as author (data/).
- Drawings: patent figures FIG. 1 to FIG. 9 in SVG and an 11 x 17 doctor-pharmacist chart.
- Patent papers: the application text and claims (Evidence 8, 9), paste-ready filing texts, filing checklist, figure descriptions, the filed DOCX, the USPTO forms and the N417 receipt (Evidence 4, 10).
- Research and product documents: seven research reports, the formulation specification, the regulatory ship-status file and the product valuation.
- Package documentation: README, LICENSE, MANIFEST.json, CITATION.cff, CHANGELOG, google_patents_search_list.txt, a copy of the master IP register and three sales-pitch files.
A second copy of 87 working files (tool caches excluded) under D:/special/45-fda-rebuttles-and-adwork/22-brain-chemistry/ carries a byte-identical LICENSE and adds the owner's regulatory-positioning memos.
Ownership. The LICENSE, headed "PROPRIETARY AND CONFIDENTIAL", states that the Work is "the exclusive property of Christopher Gabriel Brown." (Evidence 2). He is the sole inventor and the first named inventor on the USPTO receipt for 19/555,525 (Evidence 3, 8). No assignment is of record.
What a buyer receives. The LICENSE reads "NO LICENSE IS GRANTED." (Evidence 2). The item page states "No intellectual property is conveyed with purchase." (Evidence 15). The purchase term at https://cri-one.com/terms reads "When you buy, you buy the use of that blueprint only." (D:/special/crione-static/pages/terms/index.html).
Secrecy measures (18 U.S.C. 1839(3)). Full packages go only to paying buyers. The item page states that the package ships on a single Blu-ray disc whose archive is AES-256 encrypted, with the passphrase sent separately by email once the disc is despatched (Evidence 15). Every purchase is made under the mutual NDA, Version 2026-10-08, published at https://cri-one.com/nda/: the buyer accepts it by ticking the agreement box at Stripe checkout, and the executed copy is emailed to both parties (D:/special/crione-static/pages/nda/index.html). The public item page carries only the description; the code, databases, drawing files, reports and application papers stay inside the delivered package.
3. First Art - The Earliest Dated Disclosure
| Date | Record | What it discloses | Source |
|---|---|---|---|
| 24 Nov 2017 | Invent Depositions, ISBN 978-1-979767-89-7, deposition #769, page 181 | The proper chemicals in the brain without poisoning other organs | Evidence 11, 12 |
| 2017 (entry mark) | 2017 catalog, deposition #133 | Diagnosing dopamine, serotonin, adrenaline and histamine receptor-site changes | Evidence 11 |
| 2017 (entry mark) | 2017 catalog, deposition #251 | Element valences and their properties in the brain versus other organs | Evidence 11 |
| 2017 (entry mark) | 2017 catalog, deposition #148 | Healthy-human chemistry balanced organ by organ, the brain included | Evidence 11 |
| 3 Mar 2026 | U.S. Application No. 19/555,525 received | Seven-compound composition, formulation method, method of use, computational design method; 24 claims | Evidence 3, 8, 9 |
| 6 Mar 2026 | Store listing "NeuroElement Brain Supplement" created | Public listing of the formulation line | Evidence 13 |
Deposition anchors (D:/Rebuttals/_registers/DEPOSITIONS_A.json, confirmed in the master IP register, Evidence 11):
- #769, anchor printed book page 181 (Evidence 12), register line 1500: "chemical balance relation goal is the chance to achieve the proper chemicals in the brain or an organ to make it work better and function regulatory like while not poisoning the other organs"
- #133, anchor 2017 catalog, entry marked copyright © 2017 chris g brown, register line 369: "mission 1 diagnose changes at dopa mine serotonin adrenaline and histamine receptor sites in the central nervous system by using a similar method to diabetic blood testing." The owner's origin-story file maps #133 to Project 22 (D:/manager/book-ocr-2017-invent-depositions/origin-stories/neurotransmitter-diagnostic-deposition-133.md).
- #251, anchor 2017 catalog, register line 926: "sodium delineation native valances and their properties in the brain verses muscles and other organs."
The master IP register D:/special/82-alchemy-calc-two/1 light trigger.txt (1,769 lines) is the source of record; the package's own copy of the register carries #133 and #769 at the same line numbers.
Defensive-publication effect. Under 35 U.S.C. 102(a)(1), a printed publication or other public availability before a filing date is prior art against that filing. The 2017 depositions stand against every later filer on the brain chemical-balance and element-valence subject matter they disclose. The item page of 8 October 2026, which publishes the seven compounds, their doses and the divided schedule, stands against every later filer on that matter (Evidence 15). A challenger must produce a dated record earlier than 24 November 2017 disclosing the same research line, or earlier than 3 March 2026 disclosing the same seven-compound combination. None is of record.
Prior Art Considered and Distinguished
The owner's filed application text names and distinguishes its prior art in paragraph [0009], and its filing checklist rates each reference (Evidence 8; D:/special/22-brain-chemistry/patent_application/FILING_CHECKLIST_AND_IP_ANALYSIS.md).
| Reference | Title as recorded | Distinction |
|---|---|---|
| US 9,301,966 B2 | Magnesium compositions and uses thereof | Magnesium L-threonate alone or with limited excipients; here it is one of seven components |
| US 8,734,855 B2 | Slow release metal amino acid chelates | Generic "additional metal ions"; no specific BBB-crossing combination, rationale or recipe |
| US 2022/0054537 A1 | Title not recorded | Mg L-threonate with neurotransmitter precursors; no ebselen, iron bisglycinate or NAC |
| US 2022/0233484 A1 | Title not recorded | Mg L-threonate with homotaurine; one disease, two components |
| CN 114304610 A | Title not recorded | Mg-threonate with metal ions; no seven-component combination or computational method |
Paragraph [0009] also distinguishes the Oxford University ebselen patents (Cowen et al.), directed to ebselen alone, and the Alterity Therapeutics iron chaperone patents, directed to iron redistribution within the brain. Paragraph [0010] states that no known prior art discloses or suggests the seven-compound combination, its formulation recipe and mixing method, or the computational design method (Evidence 8).
The portfolio-wide references keyed to this product (US 4,775,876, US 2012/0305059 A1, US 2010/0183919 A1, US 6,175,719 B1, US 7,418,236 B2, US 11,258,379 B2) address photon recycling, quantum-dot energy storage, satellite communications and quantum energy harvesting, fields apart from brain chemistry (D:/Rebuttals/_registers/PRIOR_ART_REGISTER.json). The package's google_patents_search_list.txt indexes 34 of the owner's own U.S. application numbers and names no third-party reference.
4. First to File - The USPTO Record
| U.S. Application | Filed | Status of record | What it covers for this product | Source |
|---|---|---|---|---|
| 19/555,525 | 3 Mar 2026 | Pending; Filing Receipt mailed 13 Aug 2026 | The package subject matter: 24 claims, 4 independent | Evidence 3, 4, 5, 9 |
| 19/693,405 | 30 May 2026 | Pending; Filing Receipt mailed 25 Jun 2026 | Flagship umbrella; Brain Chemistry is Project 22 of its as-filed catalog | Evidence 6, 7 |
Every application is dated by its own effective filing date. The USPTO Electronic Acknowledgement Receipt for 19/555,525 records receipt at 03/03/2026 05:06:50 PM ET, Patent Center No. 74702743, Confirmation No. [redacted], under the title "FRAGILE MULTI-ELEMENT NEUROTHERAPEUTIC COMPOSITION WITH FORMULATION METHOD AND COMPUTATIONAL METHOD FOR DESIGNING MULTI-TARGET BRAIN DISEASE TREATMENTS" (Evidence 3). The N417 receipt inside the package is byte-identical to the USPTO receipt on file (Evidence 4). The Filing Receipt of 19/555,525 shows no domestic benefit claim, and the 19/693,405 Filing Receipt lists none; each application stands on its own date (D:/Rebuttals/_registers/USPTO_REGISTER.json). A challenger must produce an application with an effective filing date before 3 March 2026 claiming the same seven-compound combination or the same computational design method. None is of record.
Marking line: Patent pending - U.S. Application Nos. 19/555,525 and 19/693,405.
5. First to Market - The Dated Public Offering
| Date | Event | Where | Source |
|---|---|---|---|
| 6 Mar 2026 | Listing "NeuroElement Brain Supplement" (SKU 1525488) created; online in the 8 Apr 2026 export | cri-one.com, old store | Evidence 13 |
| 19 Apr 2026 | Provenance ledger lists the listing as first posted | cri-one.com/store/ | D:/manager/first-to-market/first-to-market-LEDGER.csv |
| 31 Aug 2026 | Blueprint record 22-brain-chemistry (SKU 2051) created | cri-one.com, old store | D:/manager/_store/export_catalog_product_20260831_201548.csv |
| 1 Sep 2026 | Record re-created; kept in the 7 Sep 2026 export | cri-one.com, old store | D:/manager/export_catalog_product_20260907_110415.csv |
| 4 Sep 2026 | Delivery file 22-brain-chemistry__2026-09-04.zip dated | Delivery copies | D:/special/crione-static/delivery-v2/product_deliverables.csv |
| 8 Oct 2026, 03:55 UTC | First new-site email campaign to US company prospects started | cri-one.com mail | C:/Users/cri-one/.claude/projects/D--special/memory/crione-new-server-2026-10-08.md; D:/special/_mailer/campaigns/new-site-2026-10/campaign.json |
| 8 Oct 2026 | Item page published | cri-one.com/inventory/item-8470/ | Evidence 15 |
| 8 Oct 2026, 05:06 UTC | Stripe card Payment Link (created 04:56:01Z) public as the Buy button | Item page | Evidence 14 |
6. Copyright
Notice: "Copyright (c) 2026 Christopher Gabriel Brown. All rights reserved." (package LICENSE, Evidence 2). The 2017 depositions cited here (#133, #148, #251, #769) each carry the mark "copyright © 2017 chris g brown" in the master IP register (Evidence 11).
Works covered. Text (the application text, seven research reports, the formulation specification), drawings (FIG. 1 to FIG. 9 and the 11 x 17 chart), code (23 Python files), data compilations (five JSON databases) and web pages (the product description pages and the SVG generator page). Copyright protects this expression; the composition and the methods are held by the patent filings and by confidentiality (17 U.S.C. 102(b)).
Registrations. The owner's written corpus is anchored by 20 registrations marked verified in D:/Rebuttals/_registers/COPYRIGHT_REGISTER.json, effective 1 October 2010 to 15 March 2026, among them TX 8-396-625 (abstract, 2017), TX 8-657-127 (buy text, 2018) and TX 9-504-677 (estimated, 2025). The 2026 package is protected from fixation (17 U.S.C. 102(a)); registration is the gateway to suit for U.S. works (17 U.S.C. 411(a)), and a certificate made within five years of first publication is prima facie evidence of validity (17 U.S.C. 410(c)).
Human authorship. Protection covers the human-authored expression and the author's selection, coordination and arrangement (U.S. Copyright Office registration guidance, March 2023). The protectable core here is human-authored: the numbered depositions written by Christopher Gabriel Brown and his selection, coordination and arrangement of this package. CITATION.cff and each JSON database name him as author.
Notice practice. The notice sits in the LICENSE, the sales-pitch product card (sales-pitches/brain-chemistry26_PRODUCT_CARD.md) and the item page; it defeats an innocent-infringer defense (17 U.S.C. 401(d)).
7. Firm Rebuttals
Challenge 1 - "Every one of these seven compounds is already on the market. Nothing here is original."
Rebuttal. The owner claims the combination and the methods, and the filed text says so. Claim 1 recites the seven compounds together, delivering at least ten brain-essential elements; claim 3 recites the divided morning and evening regimen; claim 12 the formulation method; claim 20 the computational design method (Evidence 9). Paragraph [0010] records that no known prior art discloses or suggests that combination, that recipe or that method, and paragraph [0009] distinguishes each reference by name (Evidence 8). A challenger must produce a dated record earlier than 3 March 2026 disclosing the same seven-compound combination. None is of record.
Challenge 2 - "Someone filed first."
Rebuttal. Under first-inventor-to-file, the challenger must produce an application with an effective filing date before 3 March 2026 claiming the same combination or the same computational design method. None is of record. Any later filer meets the 2017 depositions and the published item page as prior art under 35 U.S.C. 102(a)(1) (Evidence 11, 12, 15).
Challenge 3 - "There is no issued patent, so there is nothing to respect."
Rebuttal. The owner holds U.S. Application No. 19/555,525 and U.S. Application No. 19/693,405, both filed and pending (Evidence 3, 5, 6). "Patent pending" marking is correct while an application is pending (35 U.S.C. 292). The package is also held by copyright, by the trade-secret measures of record and by its dated public record.
Challenge 4 - "It was published, so it is free to use."
Rebuttal. Publication is disclosure, not a grant. The LICENSE reads "NO LICENSE IS GRANTED." (Evidence 2); the item page states "No intellectual property is conveyed with purchase." (Evidence 15); the purchase term grants the use of that blueprint only. The first store listing, created 6 March 2026, postdates the 3 March 2026 filing, so it is not prior art against 19/555,525 under 35 U.S.C. 102(a)(1) (Evidence 3, 13). Copyright continues after publication.
Challenge 5 - "AI made it, so there is no copyright."
Rebuttal. The protectable core is human-authored: the 2017 depositions written by Christopher Gabriel Brown (Evidence 11, 12), the five databases whose metadata names him as author (D:/special/22-brain-chemistry/data/), and his selection, coordination and arrangement of this package. The March 2023 Copyright Office guidance recognizes exactly that. The Declaration under 37 CFR 1.63 filed with 19/555,525 names him as the inventor (Evidence 10).
Challenge 6 - "The dates can be faked."
Rebuttal. The dates rest on third-party records. ISBN 978-1-979767-89-7 identifies the CreateSpace edition first shipped 24 November 2017 (D:/manager/book-ocr-2017-invent-depositions/MANIFEST.md). Internet Archive first captures date crioner.com to 23 January 2010, cri-one.com to 28 January 2011 and buyinvent.com to 5 March 2014 (D:/manager/first-to-market/wayback_evidence.json). The USPTO Acknowledgement Receipt prints a SHA-512 message digest for each filed document, and the SHA-512 digests of the package's aia0001.pdf and sb0015a.pdf equal two of those printed digests character for character: the package holds the very forms the USPTO received on 3 March 2026 (Evidence 3, 10). Stripe stamped the Payment Link 2026-10-08T04:56:01Z (Evidence 14). This record's files are fingerprinted by SHA-256 in D:/Rebuttals/_evidence/8470.sha256.
Challenge 7 - "The claims name brain diseases, so this is a medical product making treatment claims."
Rebuttal. This is a research and discovery IP record and makes no treatment claim to anyone. The item sold is the blueprint package; the item page states "The deliverable is not a supplement bottle." (Evidence 15). Patent claims define the scope of the right sought at the USPTO; they represent to no one that a composition works. The package's regulatory ship-status file keeps any manufacturing decision separate from the patent record: "Patent claim ≠ commercial availability." (D:/special/22-brain-chemistry/product/REGULATORY_STATUS.md).
Challenge 8 - "85 percent mechanism coverage and 89 percent disease coverage are numbers pulled from the air."
Rebuttal. The owner's filed text defines both figures, and the record holds them exactly. The Mechanism Coverage Score is MCS = |Union(mechanisms)| / 40 and the Disease Coverage Score is "the number of catalogued diseases for which at least one implicated element is present in the combination, divided by the total number of diseases", with DCS = |diseases covered| / 18 (paragraph [0035], Evidence 8). The preferred combination achieves "an MCS of 34/40 (0.85) and a DCS of 16/18 (0.89), for a Combined Score of 0.87", with equal weights alpha = beta = 0.5 (paragraphs [0035] and [0036], Evidence 8). FIG. 2 and FIG. 3 chart the same 34/40 and 16/18 results. They are database-coverage scores, quoted exactly as filed.
Challenge 9 - "It is just an idea."
Rebuttal. The package is concrete work product: 5,998 lines of Python with a command-line tool, a REST API and a test suite; five JSON databases; nine patent figures; seven research reports; a formulation specification; and the filed application papers with the USPTO receipt (Section 2; Evidence 1, 4, 8, 9).
8. Evidence Index
| # | File | SHA-256 (first 16 hex) | What it proves |
|---|---|---|---|
| 1 | D:/special/_inventory/catalog-export-20260907/2051_22-brain-chemistry.md | 48cd03b793c9321c | Catalog description and package contents |
| 2 | D:/special/22-brain-chemistry/LICENSE | e946379bc37eace7 | Copyright notice, exclusive property, no license granted |
| 3 | D:/USPTO Responses/Receipts/N417 (14).pdf | ca48a9d5f3d7e7f8 | 19/555,525 receipt date, time, numbers and digests |
| 4 | D:/special/22-brain-chemistry/patent_application/N417 (1).pdf | ca48a9d5f3d7e7f8 | Identical receipt inside the package |
| 5 | D:/USPTO Responses/EPSCAN/20160101_000000(4).PDF | 25e1c9149b4c88ed | 19/555,525 status papers of 13 Aug 2026 |
| 6 | D:/USPTO Responses/EPSCAN/20160101_000000(35).PDF | b858723d9abb8e1e | 19/693,405 Filing Receipt |
| 7 | D:/manager/work/2 current_work_catalog.txt | 5b7a680d2563d031 | Project 22 in the as-filed umbrella catalog |
| 8 | D:/special/22-brain-chemistry/patent_application/NONPROVISIONAL_UTILITY_PATENT_APPLICATION.md | 2ec31f1d9cedb606 | Prior art [0009]-[0010]; MCS and DCS [0035]-[0036] |
| 9 | D:/special/22-brain-chemistry/patent_application/PASTE_READY_CLAIMS.txt | 01f45c7a162af91d | 24 claims, four independent |
| 10 | D:/special/22-brain-chemistry/patent_application/aia0001.pdf | 2048e1845d80bb6b | Filed Oath or Declaration; SHA-512 matches receipt |
| 11 | D:/special/82-alchemy-calc-two/1 light trigger.txt | 2dcb359de3f1b56d | Master IP register; depositions #133, #148, #251, #769 |
| 12 | D:/manager/book-ocr-2017-invent-depositions/entries-index.csv | 9e72c4638df2ca6e | Deposition #769 on printed page 181 |
| 13 | D:/manager/export_catalog_product_20260408_165843.csv | 1ec6bd9793cf5541 | Store listing created 6 Mar 2026 |
| 14 | D:/special/crione-static/delivery-v2/payment_links_ledger.live.json | 96abb64653254b86 | Stripe Payment Link timestamp |
| 15 | D:/special/crione-static/site-inventory/inventory/item-8470/index.html | 2ac98c00b7f890c0 | Public item page, no-IP-conveyed statement, notice |
9. Notice Line
© 2017-2026 Christopher Gabriel Brown (CRI-ONE). All rights reserved. Patent pending - U.S. Application Nos. 19/555,525 and 19/693,405.
cri-one.com/22-brain-chemistry.html
Also sold as part of Cri-One Health 2026 · $10.08B.
Payment is by bank transfer through Stripe.Go to cart